

CITATION REPORT

List of articles citing

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

DOI: 10.1016/s0002-9149(99)00042-9

American Journal of Cardiology, 1999, 83, 3C-12C.

Source: <https://exaly.com/paper-pdf/30566179/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
412	Medical treatment of erectile dysfunction. 1999 , 31, 388-98		24
411	Sildenafil (Viagra) and ophthalmology. 1999 , 44, 153-62		136
410	Viagra and Cardiovascular Disease. 1999 , 4, 259-267		12
409	Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. 2000 , 84, 316-24		12
408	Safety of sildenafil. 2000 , 10, 613-5		2
407	Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). 2000 , 60, 1333-41		41
406	Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. <i>American Journal of Cardiology</i> , 2000 , 86, 23F-26F	3	30
405	Cardiovascular risk and sildenafil. <i>American Journal of Cardiology</i> , 2000 , 86, 57F-61F	3	65
404	Effect of sildenafil on coronary active and reactive hyperemia. 2000 , 279, H2319-25		21
403	Hemodynamic effects of sildenafil in men with severe coronary artery disease. 2000 , 342, 1622-6		257
402	Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. 2000 , 102, 3032-8		325
401	Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. 2000 , 102, 2997-3002		49
400	Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. 2000 , 20, 529-37		123
399	Sex and the patient with cardiovascular risk factors: focus on sildenafil. 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S		32
398	Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. 2000 , 70, 1327-31		33
397	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 56, 545		4
396	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 56, 545-546		

395	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 55, 146-50	109
394	Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. 2000 , 36, 25-31	146
393	Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. 2000 , 36, 845-51	250
392	Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. 2001 , 37, 286-92	39
391	Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. 2001 , 37, 1981-8	19
390	IN VIVO AND IN VITRO INVESTIGATION OF THE EFFECTS OF SILDENAFIL ON RAT CAVERNOUS SMOOTH MUSCLE. 2001 , 165, 1010-1014	21
389	Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. 2001 , 33, 575-80	44
388	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23	65
387	DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. 2001 , 165, 1004-1009	11
386	Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. 2001 , 59, 1044-50	60
385	Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. 2001 , 37, 413-21	53
384	Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate. 2001 , 38, 149-55	13
383	Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. 2001 , 360, 199-208	43
382	Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. 2001 , 103, E119-20; author reply E119-20	2
381	Evaluation of side effects of sildenafil in group of young healthy volunteers. 2001 , 32, 705-8	12
380	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. 2001 , 15, 707-13	77
379	Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. 2001 , 411, 161-168	26
378	Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. 2001 , 412, 155-69	29

377	The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. 2001 , 420, 55-65	43
376	Basal tonic release of nitric oxide coupled to cGMP production regulates the vascular reactivity of the mesenteric bed. 2001 , 424, 221-7	17
375	FR226807: a potent and selective phosphodiesterase type 5 inhibitor. 2001 , 428, 295-302	17
374	KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. 2001 , 431, 17-24	13
373	Genetic control of coordinated changes in HDL and LDL size phenotypes. 2001 , 21, 1829-33	20
372	Transmural distribution of three-dimensional systolic strains in stunned myocardium. 2001 , 104, 336-41	28
371	Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. 2001 , 38, 940-6	30
370	Hemorrhoidal bleeding associated with sildenafil. 2001 , 96, 2518-9	13
369	Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. 2001 , 22, 342-88	164
368	Sildenafil inhibits hypoxia-induced pulmonary hypertension. 2001 , 104, 424-8	406
367	Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. 2001 , 15, 1718-26	204
366	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7	24
365	Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. 2002 , 50, 758-64	132
364	Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. 2002 , 283, H1263-9	218
363	Molecular mechanisms of cardiostimulatory effects of sildenafil. 2002 , 88, 362-4	9
362	Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. 2002 , 94, 1505-9, table of contents	1
361	Sildenafil (Viagra) Augments Sodium Nitroprusside-Induced But Not Nitroglycerin-Induced Hypotension in Dogs. 2002 , 94, 1505-1509	9
360	Effect of sildenafil on renin secretion in human subjects. 2002 , 227, 620-5	13

359	Sildenafil induces retinal vasodilatation in healthy subjects. 2002 , 86, 156-8	44
358	Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. 2002 , 282, H1787-92	9
357	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. 2002 , 40, 1232-40	238
356	Cardiovascular activity ¹ . 2002 , 26-276	
355	Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. 2002 , 106, 1097-103	150
354	Management of Erectile Dysfunction. 2002 , 10, 431-452	5
353	Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11	117
352	T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters. 2002 , 443, 179-84	2
351	Mechanisms of action of nitric oxide in the brain stem: role of oxidative stress. 2002 , 98, 24-7	46
350	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. 2002 , 86, 131-41	64
349	Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. 2002 , 440, 45-52	28
348	Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. 2002 , 456, 91-8	22
347	Inhibition of platelet P2Y ₁₂ and alpha _{2A} receptor signaling by cGMP-dependent protein kinase. 2002 , 64, 433-9	9
346	Xanthine-analog, KMUP-2, enhances cyclic GMP and K ⁺ channel activities in rabbit aorta and corpus cavernosum with associated penile erection. 2002 , 55, 162-172	2
345	Introduction. 2002 , 53, 1S-3S	3
344	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25
343	The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. 2002 , 22, 1124-31	99
342	KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K ⁽⁺⁾ channels. 2002 , 135, 1159-66	38

341	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 , 4, 457-65		69
340	Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M	3	32
339	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <i>American Journal of Cardiology</i> , 2003 , 92, 9M-18M	3	160
338	Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859. 2003 , 472, 73-80		14
337	Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. 2003 , 9, 9-15		27
336	Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. 2003 , 8, 14-7		10
335	Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. 2004 , 57, 209-12		24
334	T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo. 2003 , 140, 1283-91		7
333	Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. 2003 , 15, 347-54		47
332	What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. 2003 , 15, 412-7		23
331	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21		6
330	Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. 2003 , 163, 1567-77		81
329	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44		124
328	Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. 2003 , 101, 265-9		111
327	Should the patient with coronary artery disease use sildenafil?. 2003 , 6, 161-5		11
326	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
325	A stimulatory role for cGMP-dependent protein kinase in platelet activation. 2003 , 112, 77-86		221
324	Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. 2003 , 90, 153-7		13

323	Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. 2003 , 108, 2172-83	267
322	Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. 2003 , 100, 5531-6	50
321	Phosphodiesterase type 5 (PDE5) inhibitors. 2003 , 41, 249-306	23
320	Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. 2003 , 126, 241-7	231
319	Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?. 2003 , 108, 2831-3	
318	The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. 2003 , 55, 271-324	247
317	Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. 2003 , 64, 533-46	260
316	Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. 2003 , 12, 133-5	31
315	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. 2003 , 41, 734-43	42
314	Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. 2003 , 284, H1513-20	28
313	cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. 2003 , 372, 419-26	28
312	Persistent pulmonary hypertension of the newborn. 2004 , 65, 418-21	
311	Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. 2004 , 13, 332-5	
310	The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. 2004 , 18, 1382-91	78
309	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. 2004 , 24, 63-8	30
308	Tissue expression, distribution, and regulation of PDE5. 2004 , 16 Suppl 1, S8-S10	58
307	Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. 2004 , 16 Suppl 1, S34-7	62
306	Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. 2004 , 141, 114-22	5

305	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. 2004 , 19, 74-9		1
304	The impact of sildenafil on molecular science and sexual health. 2004 , 46, 9-14		8
303	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. <i>American Journal of Cardiology</i> , 2004 , 94, 1475-7	3	107
302	Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. 2004 , 67, 1559-67		62
301	Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. 2004 , 190, 1283-90		51
300	The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits. 2004 , 32, 107-11		19
299	Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. 2004 , 1, 183-9		24
298	Expression of PDE5 splice variants during ontogenesis of chick dorsal root ganglia. 2004 , 78, 815-23		5
297	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94		14
296	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88		69
295	The discovery and development of Viagra [®] (sildenafil citrate). 2004 , 1-13		4
294	Visual short-term effects of Viagra: double-blind study in healthy young subjects. 2004 , 137, 842-9		50
293	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506		53
292	Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. 2004 , 25, 625-9		42
291	Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794		49
290	GPIIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. 2004 , 103, 2601-9		79
289	The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. 2005 , 128, 3065-73		31
288	Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue. 2005 , 55, 292-6		37

287	[Recent progress in cyclic nucleotide phosphodiesterase research: isozymes, functions, and inhibitors]. 2005 , 126, 121-7		6
286	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. 2005 , 64, 123-36		2
285	Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. 2005 , 32, 728-34		33
284	The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. 2005 , 17, 331-9		55
283	Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. 2005 , 521, 105-14		22
282	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. <i>American Journal of Cardiology</i> , 2005 , 96, 47M-51M	3	150
281	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. 2005 , 42, 219-32		155
280	Effects of sildenafil on major arterial blood flow using duplex sonography. 2005 , 33, 173-5		3
279	Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5. 2005 , 15, 4085-90		5
278	Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. 2005 , 164, 626-9		44
277	Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. 2005 , 37, 785-9		2
276	Involvement of β -Adrenergic Receptor Activation in Human Corpus Cavernosum Function. 2005 , 72, 57-62		
275	Effect of sildenafil citrate on the cardiovascular system. 2005 , 38, 1303-11		8
274	Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. 2005 , 288, L1193-200		18
273	Type 5 phosphodiesterase inhibition: the focus shifts to the heart. 2005 , 112, 2589-91		14
272	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. 2005 , 112, 2642-9		142
271	Expression of PDE11A in normal and malignant human tissues. 2005 , 53, 895-903		48
270	Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. 2005 , 280, 12944-55		272

- 269 Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. **2005**, 1, 283-93 34
- 268 Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. **2005**, 111, 742-6 113
- 267 Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. **2005**, 102, 1661-6 196
- 266 Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. **2005**, 127, 1647-53 183
- 265 Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. **2005**, 172, 105-13 266
- 264 Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. **2005**, 32, 419-29, vi 34
- 263 Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. **2005**, 337, 382-5 30
- 262 Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. **2005**, 6, 76 25
- 261 Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. **2006**, 15, 733-42 26
- 260 Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. **2006**, 316, 654-61 60
- 259 Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. **2006**, 77, 170-2 4
- 258 Hypotensive potential of sildenafil and tamsulosin during orthostasis. **2006**, 26, 667-71 6
- 257 Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. **2006**, 47, 1471-7 17
- 256 Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. **2006**, 127, 41-9 30
- 255 Effects of sildenafil on hypoxic pulmonary vascular function in dogs. **2006**, 101, 1085-90 28
- 254 Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. **2006**, 393, 21-41 95
- 253 Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. **2006**, 17, 493-9 8
- 252 Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets. **2006**, 26, 99-106 12

251	Nasal obstruction as a common side-effect of sildenafil citrate. 2006 , 208, 251-4	27
250	Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. 2006 , 98, 1259-63	136
249	Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. 2001 , 19, 369-86	141
248	Pathophysiology and treatment of diabetic erectile dysfunction. 2006 , 8, 675-84	88
247	Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. 2006 , 62, 280-7	16
246	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
245	Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction. 2006 , 18, 432-7	5
244	Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution. 2006 , 16, 1371-9	16
243	Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. 2006 , 41, 593-7	31
242	[Unilateral temporary vision loss in an otherwise healthy elderly patient]. 2006 , 103, 224-7	
241	The emerging role for type 5 phosphodiesterase inhibition in heart failure. 2006 , 3, 123-8	12
240	Phosphodiesterase-5 inhibitors and their hemodynamic effects. 2006 , 8, 345-51	23
239	Sildenafil citrate induces migration of mouse aortic endothelial cells and proteinase secretion. 2006 , 11, 402-407	1
238	Relaxant effect of sildenafil in the rabbit basilar artery. 2006 , 44, 10-6	11
237	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. 2006 , 542, 141-7	30
236	Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. 2006 , 541, 184-90	26
235	Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. 2006 , 26, 369-95	31
234	Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics. 2006 , 95, 435-45	9

233	Influence of intravenous sildenafil on cerebral oxygenation measured by near-infrared spectroscopy in infants after cardiac surgery. 2006 , 59, 462-5	32
232	Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. 2006 , 113, 2221-8	210
231	Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. 2006 , 99, 816-28	307
230	Hypoxia converts human macrophages into triglyceride-loaded foam cells. 2006 , 26, 1871-6	125
229	Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. 2006 , 92, 170-6	27
228	Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. 2007 , 282, 32749-57	81
227	cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. 2007 , 100, 1569-78	255
226	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48	45
225	Phosphodiesterase type 5: expanding roles in cardiovascular regulation. 2007 , 101, 1084-95	164
224	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64	24
223	Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. 2007 , 56, 1025-33	186
222	Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. 2007 , 100, 489-501	74
221	Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. 2007 , 110, 2166-72	269
220	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
219	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. 2007 , 116, 238-48	420
218	Cardiovascular Activity. 2007 , 47-391	
217	Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. 2007 , 8, 965-74	16
216	Acquired Disorders of Platelet Function. 2007 , 1051-1076	5

215	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. 2007 , 150, 567-76	42
214	Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. 2007 , 572, 49-56	9
213	Effect of sildenafil and rolipram on adrenergic responses in isolated human and monkey corpus cavernosum. 2007 , 52, 253-8	6
212	Structural genomics and drug discovery. 2007 , 11, 224-38	63
211	Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. 2007 , 21, 171-94	61
210	Nonurologic applications of phosphodiesterase type 5 inhibitors. 2007 , 4, 64-70	1
209	Gene expression and protein localization of calmodulin-dependent phosphodiesterase during ontogenesis of chick retina. 2008 , 86, 1017-23	3
208	Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein. 2008 , 154, 1216-24	12
207	The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. 2008 , 589, 180-7	27
206	Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6	26
205	The use of phosphodiesterase 5 inhibitors with concomitant medications. 2008 , 31, 799-808	49
204	Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. 2009 , 81, 301-9	40
203	The cardiovascular safety of tadalafil. 2008 , 7, 43-52	8
202	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. 2008 , 294, H1398-H1406	90
201	Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. 2009 , 331, 842-50	37
200	Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?. 2009 , 1, 179-97	15
199	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 2009 , 6, 349-55	25
198	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 2009 , 21, 149-57	12

197	Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. 2009 , 119, 628-47	525
196	Role of Ca ²⁺ /calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. 2009 , 105, 956-64	129
195	Cardiovascular effects of phosphodiesterase type 5 inhibitors. 2009 , 6, 658-74	38
194	Erectile dysfunction in diabetes mellitus. 2009 , 6, 1232-47	247
193	The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. 2009 , 620, 78-83	29
192	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. 2009 , 56, 1067-73	15
191	Phosphodiesterase inhibition in heart failure. 2009 , 14, 255-63	51
190	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24	45
189	The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors. 2010 , 121, 370-6	18
188	Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. 2009 , 74, 216-21	10
187	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 2009 , 28, 676-82	40
186	Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12	29
185	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. 2010 , 3, 507-15	38
184	Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. 2010 , 5, 1927-36	17
183	Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. 2010 , 64, 15-22	8
182	Cardiac Depression Produced by L-Arginine and Phosphodiesterase Inhibitor on Isolated Mammalian Rabbit Heart: Function of Cyclic Guanosine Monophosphate (cGMP). 2010 , 5, 71-79	
181	Effect of sildenafil on neuropathic pain and hemodynamics in rats. 2010 , 51, 82-7	16
180	A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. 2010 , 30, 1315-24	51

179	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. 2010 , 122, 88-95	78
178	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. 2010 , 62, 525-63	677
177	Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. 2010 , 30, 239-45	98
176	Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 2010 , 22, 68-76	19
175	Sildenafil protects epithelial cell through the inhibition of xanthine oxidase and the impairment of ROS production. 2010 , 44, 232-9	10
174	Longer time to peak flow predicts better arterial flow parameters on penile Doppler ultrasound. 2010 , 75, 112-6	8
173	Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy. 2011 , 323-44	24
172	Anti-platelet therapy: phosphodiesterase inhibitors. 2011 , 72, 634-46	182
171	Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. 2011 , 25, 129-36	139
170	Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. 2011 , 8, 109-118	2
169	An ex vivo standardized assay to measure human platelet cGMP. 2011 , 64, 164-7	9
168	PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials. 2011 , 2011, 392542	3
167	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. 2011 , 91, 651-90	443
166	cGMP phosphodiesterase inhibition improves the vascular and metabolic actions of insulin in skeletal muscle. 2011 , 301, E342-50	17
165	Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. 2011 , 300, H2272-9	58
164	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. 2012 , 44, 766-75	22
163	Vardenafil for the treatment of erectile dysfunction. 2012 , 9, 39-48	1
162	Phosphodiesterases and cyclic GMP regulation in heart muscle. 2012 , 27, 248-58	38

161	Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. 2012 , 55, 10540-50	24
160	Docking-based CoMFA and CoMSIA analyses of tetrahydro- β -carboline derivatives as type-5 phosphodiesterase inhibitors. 2012 , 27, 730-43	10
159	Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound. 2012 , 26, 690-700	6
158	Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. 2012 , 90, 328-36	54
157	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. 2012 , 59, 1921-7	58
156	Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. 2012 , 84, 1045-54	19
155	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. 2012 , 9, 192-9	26
154	Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates. 2012 , 253-290	6
153	Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. 2012 , 165, 1288-305	224
152	The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. 2012 , 14, 644-9	22
151	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. 2013 , 15, 475-83	42
150	Reproductive sequelae of diabetes in male patients. 2013 , 42, 899-914	15
149	The effect of cilostazol on right heart function and pulmonary pressure. 2013 , 31, e88-93	4
148	New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. 2013 , 8, 733-51	24
147	Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine. 2013 , 167, 848-54	6
146	Acquired Disorders of Platelet Function. 2013 , 1049-1073	1
145	Therapeutic potential of PDE modulation in treating heart disease. 2013 , 5, 1607-20	24
144	Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. 2013 , 304, H1370-81	16

143	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. 2013 , 3, 84-7	14
142	Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?. 2013 , 19, 99-103	18
141	Udenafil for the treatment of erectile dysfunction. 2014 , 10, 341-54	16
140	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2014 ,	
139	Perspectives: Coronary microvascular dysfunction in post-infarct remodelled myocardium. 2014 , 16, A74-A79	4
138	Sildenafil mediates blood-flow redistribution and neuroprotection after neonatal hypoxia-ischemia. 2014 , 45, 850-6	41
137	Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication. 2014 , 307, R396-404	15
136	The effects of combined free radical scavenger and sildenafil therapy on age-associated erectile dysfunction: An animal model. 2014 , 6, 314-20	7
135	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
134	Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. 2014 , 12, 1880-9	49
133	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. 2014 , 128, 43-56	23
132	Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial. 2014 , 15, 333	6
131	Physical activity on endothelial and erectile dysfunction: a literature review. 2014 , 17, 125-30	35
130	Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. 2014 , 40, 803-12	14
129	Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. 2015 , 51, 22-36	5
128	The emperor@ new clothes: PDE5 and the heart. 2015 , 10, e0118664	26
127	Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015 , 116, 618-21	3 3
126	Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo. 2015 , 764, 508-519	8

125	Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets. 2015 , 7, e1073435	5
124	Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction. 2015 , 47, 1098-102	3
123	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 , 147, 12-21	144
122	Sexual Dysfunction in Men and Women. 2016 , 785-830	1
121	Cardiac safety profile of sildenafil: chronotropic, inotropic and coronary vasodilator effects in the canine isolated, blood-perfused heart preparations. 2016 , 41, 739-744	1
120	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. 2016 , 9,	13
119	Anti-platelet therapy in small animal medicine. 2016 , 39, 318-35	9
118	Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. 2016 , 70, 808-815	24
117	Sildenafil treatment in a nonsevere hypertensive murine model lowers blood pressure without reducing fetal growth. 2016 , 215, 386.e1-8	4
116	Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model. 2016 , 81, 136-144	11
115	Sildenafil, a cyclic GMP phosphodiesterase inhibitor, induces microglial modulation after focal ischemia in the neonatal mouse brain. 2016 , 13, 95	30
114	The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. 2016 , 38, 357-61	2
113	A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. 2016 , 124, 318-27	12
112	Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. 2017 , 129, 615-620	33
111	Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. 2017 , 43, 291-297	17
110	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. 2017 , 145, 54-63	6
109	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2017 ,	78
108	Comparison of Three-Dimensional Ligand-based Pharmacophores among 11 Phosphodiesterases (PDE 1 to PDE 11) Pharmacophores. 2017 , 38, 1033-1037	2

107	Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. 2017 , 39, 55-65	24
106	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. 2017 , 60, 6622-6637	23
105	Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy. 2017 , 12, 100	15
104	Generation and phenotypic characterization of Pde1a mutant mice. 2017 , 12, e0181087	17
103	Nitric oxide and pulmonary arterial hypertension. 2017 , 2017, 14	21
102	Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. 2018 , 76, 71-80	49
101	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. 2018 , 175, 223-231	21
100	Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. 2018 , 11, e004571	23
99	Dual Activation of Phosphodiesterases 3 and 4 Regulates Basal Spontaneous Beating Rate of Cardiac Pacemaker Cells: Role of Compartmentalization?. 2018 , 9, 1301	10
98	cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. 2018 , 113, 24	42
97	Endothelial colony forming cells from human umbilical cord blood improved severe erectile dysfunction in obese type II diabetic rats. 2018 , 207, 272-283	3
96	Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. 2018 , 6, 583-594	14
95	HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half. 2018 , 93, 1305-1314	20
94	A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. 2018 , 23, 375-386	9
93	Multiprotein Complex With TRPC (Transient Receptor Potential-Canonical) Channel, PDE1C (Phosphodiesterase 1C), and A2R (Adenosine A2 Receptor) Plays a Critical Role in Regulating Cardiomyocyte cAMP and Survival. 2018 , 138, 1988-2002	32
92	Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases. 2019 , 33, 119-128	10
91	Advances in small-molecule therapy for managing angina pectoris in the elderly. 2019 , 20, 1471-1481	
90	Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. 2019 , 166, 300-312	27

89	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. 2019 , 5, e000526	2
88	In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors. 2019 , 87, 29	
87	Phosphodiesterase expression in the normal and failing heart. 2019 , 662, 160-168	11
86	The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. 2019 , 7, 115-128	53
85	Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction. 2020 , 11, 602369	1
84	cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype. 2020 , 75, 516-525	6
83	Update of the position paper on arterial hypertension and erectile dysfunction. 2020 , 38, 1220-1234	9
82	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. 2020 , 34, 401-417	7
81	Progressive Effects of Sildenafil on Visual Processing in Rats. 2020 , 441, 131-141	0
80	Influence of sildenafil on esophageal motor function in humans: Studies using high-resolution manometry. 2020 , 32, e13840	3
79	Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial. 2021 , 35, 360-370	1
78	Novel antiplatelet targets in the treatment of acute coronary syndromes. 2021 , 32, 15-28	7
77	Effect of prucalopride on sildenafil-induced inhibition of esophageal peristalsis in healthy adults. 2021 , 36, 1556-1561	0
76	Drug Repurposing. 2021 ,	1
75	The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. 2021 , 212, 113123	4
74	New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. 2021 , 11, 627229	7
73	Cilostazol: a Review of Basic Mechanisms and Clinical Uses. 2021 , 1	5
72	Sildenafil citrate in healthy and diseased hearts. 2021 , 6, 033-039	0

71	Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?. 2021 , 8, 2365-2367	0
70	Isolation and Characterization of CD39-like Phosphodiesterase (Cc-PDE) from Cerastes cerastes Venom: Molecular Inhibitory Mechanism of Antiaggregation and Anticoagulation. 2021 , 28, 426-441	4
69	Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition. 2021 , 48, 1103-1110	0
68	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. 2021 , 11,	5
67	A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. 2021 , 93, 221-226	6
66	Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond. 2021 , 22,	2
65	Effects of pentoxifylline on canine platelet aggregation. 2021 , 7, 2178-2184	1
64	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237	1
63	Phosphodiesterase-5 Inhibition. 2004 , 117-130	1
62	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161	1
61	Dipyridamole and PDE Inhibitors. 2017 , 1283-1298	3
60	cGMP in the vasculature. 2009 , 447-67	39
59	cGMP and cGMP-dependent protein kinase in platelets and blood cells. 2009 , 533-48	71
58	Targeting phosphodiesterases in anti-platelet therapy. 2012 , 225-38	35
57	Sexual Dysfunction in Men and Women. 2011 , 778-816	2
56	IN VIVO AND IN VITRO INVESTIGATION OF THE EFFECTS OF SILDENAFIL ON RAT CAVERNOUS SMOOTH MUSCLE. 2001 , 1010-1014	2
55	Platelet count and function at high altitude and in high-altitude pulmonary edema. 2006 , 100, 690-4	43
54	Sex, drugs, and trial design: sex influences the heart and drug responses. 2014 , 124, 2375-7	10

53	Phosphodiesterase 5. 2006 ,	8
52	Sexual function in hypertensive patients receiving treatment. 2006 , 2, 447-55	31
51	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. 2020 , 27, 7168-7188	10
50	Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. 2020 , 26, 3633-3651	3
49	A Case Report of Cyanopsia after Taking Sildenafil. 2020 , 30, 59-64	1
48	Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. 2008 , 14, 6208-12	26
47	Vasorelaxant Effect of Sildenafil on Aorta and Pulmonary Artery in Rabbits. 2005 , 2, 55-59	1
46	Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium. 2016 , 7, 177-181	2
45	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. 2021 , 1	1
44	DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. 2001 , 1004-1009	
43	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194	
42	Erectile Dysfunction. 2004 , 213-223	
41	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181	
40	Effect of Phosphodiesterase-5 Inhibition on Coronary Blood Flow in Experimental Animals. 2004 , 163-177	
39	Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. 2004 , 89-116	
38	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. 2004 , 129-142	
37	Sildenafil, pharmacology of a highly selective PDE5 inhibitor. 2004 , 15-33	2
36	Vasorelaxant Effects of Sildenafil and Verapamil on Isolated Rat Aorta with and without Intact Endothelium. 2005 , 2, 142-145	1

35	Role of Phosphodiesterases in Cyclic Nucleotide Compartmentation in Cardiac Myocytes. 2006 ,	
34	Structural Genomics. 2007 , 1-27	
33	Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion. 2008 , 1, 70-4	
32	PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. 2015 , 185-193	
31	Phosphodiesterases and the Effects of Forskolin. 2015 , 1-22	
30	Studies in Isolated Organs. 2015 , 1-43	
29	Studies in Isolated Organs. 2016 , 3-39	
28	Phosphodiesterases and the Effects of Forskolin. 2016 , 645-663	
27	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. 2019 , 192-202	
26	Phosphodiesterase Inhibitors of 5 Type and Erectile Dysfunction. 2019 , 64-74	1
25	Chronic Administration of Sildenafil Citrate (Viagra) on the Frontal Cortex of Adult Male Rats: An Ultrastructural Study. 2020 , 08, 38-44	1
24	Cardiac Issues Related to Erectile Dysfunction. 2006 , 61-75	
23	Sildenafil: from the bench to the bedside. 2000 , 163, 1171-5	6
22	Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 2003 , 5 Suppl 7, S21-7	7
21	Impact of phosphodiesterase type 5 inhibitors on endothelial function. 2008 , 10, 26-30	6
20	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. 2011 , 16, e30-5	39
19	Platelets in pulmonary hypertension: a causative role or a simple association?. 2012 , 22, 145-57	13
18	Ultrastructural and morphometrical study of preimplantation endometrium in superovulated mice treated with progesterone or Sildenafil. 2013 , 11, 807-14	1

17	THE SCIENCE AND PRACTICE OF ERECTION PHYSIOLOGY: STORY OF A REVOLUTIONARY GASEOUS MOLECULE. 2019 , 130, 51-59	4
16	Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial. 2021 , 1	1
15	Study of the Efficiency of Using Type 5 Phosphodiesterase Inhibitors in the Therapy of Erectile Dysfunction in Patients with Metabolic Syndrome. 2021 , 58-69	
14	table1.docx. 2020 ,	
13	table2.docx. 2020 ,	
12	table3.docx. 2020 ,	
11	table4.docx. 2020 ,	
10	table5.docx. 2020 ,	
9	table6.docx. 2020 ,	
8	table7.docx. 2020 ,	
7	A Comprehensive Approach in the Treatment of Erectile Dysfunction in Obesity Patients. 2021 , 57-71	
6	Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.	1
5	Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. 2022 , 205, 115256	0
4	PDE5A: key enzyme to overcome platelet inhibition.	0
3	Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure. 2023 , 944, 175562	0
2	Current concepts and novel targets for antiplatelet therapy.	0
1	Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.	0